IL221030A0 - Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect - Google Patents

Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect

Info

Publication number
IL221030A0
IL221030A0 IL221030A IL22103012A IL221030A0 IL 221030 A0 IL221030 A0 IL 221030A0 IL 221030 A IL221030 A IL 221030A IL 22103012 A IL22103012 A IL 22103012A IL 221030 A0 IL221030 A0 IL 221030A0
Authority
IL
Israel
Prior art keywords
alpha
intraocular pressure
long duration
lowering effect
adrenergic agonist
Prior art date
Application number
IL221030A
Other languages
English (en)
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44169074&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL221030(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of IL221030A0 publication Critical patent/IL221030A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL221030A 2010-01-21 2012-07-19 Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect IL221030A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29691210P 2010-01-21 2010-01-21
PCT/US2011/022001 WO2011091225A2 (en) 2010-01-21 2011-01-21 Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect

Publications (1)

Publication Number Publication Date
IL221030A0 true IL221030A0 (en) 2012-09-24

Family

ID=44169074

Family Applications (1)

Application Number Title Priority Date Filing Date
IL221030A IL221030A0 (en) 2010-01-21 2012-07-19 Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect

Country Status (17)

Country Link
US (1) US9889088B2 (https=)
EP (1) EP2525793B1 (https=)
JP (3) JP2013518051A (https=)
KR (1) KR20120125305A (https=)
CN (1) CN102770135A (https=)
AU (1) AU2011207301A1 (https=)
BR (1) BR112012018154A2 (https=)
CA (1) CA2787573A1 (https=)
CL (1) CL2012002038A1 (https=)
CO (1) CO6592108A2 (https=)
IL (1) IL221030A0 (https=)
MX (1) MX2012008516A (https=)
RU (1) RU2012134065A (https=)
SG (1) SG182637A1 (https=)
TW (1) TW201141477A (https=)
WO (1) WO2011091225A2 (https=)
ZA (1) ZA201205470B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013016072A1 (en) * 2011-07-22 2013-01-31 Allergan, Inc. Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseases
CA2842866A1 (en) * 2011-07-22 2013-01-31 Allergan, Inc. Alpha-2 adrenergic modulators for treating visual disorders mediated by central visual projections from the eye
US20130046003A1 (en) * 2011-07-22 2013-02-21 Mohammed I. Dibas Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating retinal diseases
WO2014159576A1 (en) * 2013-03-14 2014-10-02 Allergan, Inc. Alpha-2 adrenergic agonist for treating intraocular pressure and ocular diseases through intravitreal and intracameral routes
TWI699205B (zh) * 2014-12-12 2020-07-21 日商興和股份有限公司 用於預防或治療青光眼之藥物療法
EP3647420B1 (en) 2017-06-27 2023-08-23 The University Of Tokyo Probe and method for detecting transcript resulting from fusion gene and/or exon skipping
US11077053B2 (en) 2018-08-21 2021-08-03 Allergan, Inc. Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia
PT4236932T (pt) * 2020-11-02 2026-02-23 Visus Therapeutics Inc Composto degradante num medicamento
WO2023086878A1 (en) * 2021-11-10 2023-05-19 Visus Therapeutics, Inc. Carbachol formulations to enhance anti-presbyopia effects

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
EP0775134A4 (en) * 1994-08-04 1997-08-13 Synaptic Pharma Corp NEW BENZIMIDAZOLE DERIVATIVES
US6495583B1 (en) * 1997-03-25 2002-12-17 Synaptic Pharmaceutical Corporation Benzimidazole derivatives
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
JP2009500409A (ja) * 2005-06-29 2009-01-08 アラーガン、インコーポレイテッド 痛みを処置するためのα２アドレナリン作動剤
JP2009525970A (ja) * 2006-02-06 2009-07-16 ニコックス エス エイ α２−アドレナリン受容体アゴニストとしてのアプラクロニジンおよびブリモドニジンのニトロオキシ含有誘導体
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration

Also Published As

Publication number Publication date
MX2012008516A (es) 2012-10-15
JP2017125074A (ja) 2017-07-20
EP2525793B1 (en) 2018-09-05
US9889088B2 (en) 2018-02-13
ZA201205470B (en) 2013-05-29
CO6592108A2 (es) 2013-01-02
RU2012134065A (ru) 2014-02-27
CN102770135A (zh) 2012-11-07
BR112012018154A2 (pt) 2016-04-05
CL2012002038A1 (es) 2012-11-16
AU2011207301A1 (en) 2012-08-09
JP2013518051A (ja) 2013-05-20
SG182637A1 (en) 2012-08-30
CA2787573A1 (en) 2011-07-28
TW201141477A (en) 2011-12-01
JP6466504B2 (ja) 2019-02-06
US20110178145A1 (en) 2011-07-21
WO2011091225A3 (en) 2012-05-18
EP2525793A2 (en) 2012-11-28
JP2016026206A (ja) 2016-02-12
KR20120125305A (ko) 2012-11-14
WO2011091225A2 (en) 2011-07-28

Similar Documents

Publication Publication Date Title
ZA201205470B (en) Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect
TWI561228B (en) Adaptive patient interface
IL222457A0 (en) Intraocular pressure reduction with intracameral bimatoprost implants
GB201003274D0 (en) Methods of connecting
ZA201209476B (en) Method of cleansing hair
PL2774120T3 (pl) Sposób uzyskiwania trybu predykcji wewnątrzobrazowej
LT3184136T (lt) Injektorius
ZA201201467B (en) One-touch artificial nail
PL2397069T3 (pl) Analiza ciśnienia wewnątrzgałkowego
EP2652062A4 (en) INDIRECT RECOVERY TECHNOLOGY
ZA201206456B (en) Uses of dgati inhibitors
GB201100847D0 (en) An artificial joint
GB2477178B (en) Improved Pump
GB2480754B (en) Engine cleaning method
PL2513060T3 (pl) Krystaliczna postać α karbabenzopirydu
GB2483682B (en) Method of securing fitted furniture
HK1176309A (en) Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect
TWM401347U (en) Improved structure of brush
GB201020252D0 (en) Method of cleaning
GB201011285D0 (en) Uses of carpet
GB201311329D0 (en) Method of cleaning
GB2482153B (en) Artificial behaviour
GB201007716D0 (en) Use of denatured CTGF
PH32010000450S1 (en) Tissue cleaner
TWM385321U (en) bath brush